Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Journal
Translational Cancer Research
Journal Volume
5
Pages
S907-S912
Date Issued
2016
Author(s)
Abstract
The 2016 publication entitled “5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage null HER2 -positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial” in null Lancet Oncology null provided an opportunity to revisit the combination of pertuzumab and trastuzumab as a neoadjuvant treatment for null HER2 -positive breast cancer (1). Pertuzumab is the first Food and Drug Administration (FDA)-approved drug in the neoadjuvant setting (2).
SDGs
Other Subjects
epidermal growth factor receptor 2; pertuzumab; trastuzumab; adjuvant therapy; breast cancer; cancer adjuvant therapy; cancer combination chemotherapy; cancer patient; cancer survival; drug use; human; long term survival; neoadjuvant therapy; Note; treatment response
Publisher
AME Publishing Company
Type
note